Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
IGI gets Fast Track FDA Designation for ISB 2001 in Multiple Myeloma
Details : ISB 2001 is a first-in-class trispecific T-cell engager that targets BCMA and CD38 on myeloma cells and CD3 on T cells. It is being investigated for relapsed or refractory multiple myeloma.
Product Name : ISB 2001
Product Type : Antibody
Upfront Cash : Inapplicable
May 05, 2025
Lead Product(s) : GRC 65327
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : National Cancer Institute
Deal Size : Undisclosed
Deal Type : Agreement
IGI and NCI Partner to Test Oral Cbl/b Inhibitor in Triple Negative Breast Cancer
Details : Under the agreement, IGI and NCI will collaborate on evaluating IGI's proprietary Cbl/b small molecule, GRC 65327, for treating triple-negative breast cancer.
Product Name : GRC 65327
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 30, 2024
Lead Product(s) : GRC 65327
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : National Cancer Institute
Deal Size : Undisclosed
Deal Type : Agreement
Certara and Ichnos Glenmark Collaborate On Cancer Drug Dosing Optimization
Details : ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells.
Product Name : ISB 2001
Product Type : Antibody
Upfront Cash : Undisclosed
September 18, 2024
Reset All
